RemeGen Biosciences, Inc.
650 Gateway Blvd, Suite No. 110
South San Francisco
About RemeGen Biosciences, Inc.
RemeGen Biosciences is a biopharmaceutical company, focusing on the discovery and development of innovative biologics for the treatment of cancer and autoimmune diseases, based in South San Francisco, California, and Rockville, Maryland. By leveraging our deep insights into oncology and immunology, advanced protein engineering/design technologies, and extensive knowledge in clinical development, our vision is to uncover the novel therapeutic targets and develop the best-in-class and first-in-class biotherapeutics for the patients with significant unmet medical needs. RemeGen Bioscience is a wholly owned subsidiary of RemeGen Inc., a global pharmaceutic company specialized in autoimmune, oncology and ophthalmic diseases.
10 articles with RemeGen Biosciences, Inc.
On Rare Disease Day 2023 RemeGen Highlights Its Social Responsibility and Rare Disease Advocacy
RemeGen Co., Ltd. continues to strengthen its social responsibility and rare disease advocacy in unison with Rare Disease Day 2023's message of continuing to increase visibility and generate change for the millions of people globally living with a rare disease, their families and carers.
RemeGen's RC118 for Injection Targeting Claudin 18.2 in Patients with Gastric and Pancreatic Cancers Granted Two Orphan Drug Designations by U.S. FDA
RemeGen Co., Ltd., a commercial-stage biotechnology company, announced on December 7, 2022, that its latest antibody-drug conjugate, RC118 for injection, has been granted two orphan drug designations by the United States Food and Drug Administration for gastric cancer and pancreatic cancer.
RemeGen Biosciences to Present New Data Updates in ACR 2022
RemeGen Co., Ltd., a leading biopharmaceutical company with fully integrated capabilities in research and discovery, clinical development, manufacturing, and commercialization of biologic drugs, will join the event of the American College of Rheumatology (ACR) 2022, hosted from November 10th to 14th.
RemeGen Biosciences to Attend ASN Kidney Week 2022
RemeGen Co., Ltd., a leading biopharmaceutical company with fully integrated capabilities in research and discovery, clinical development, manufacturing, and commercialization of biologic drugs, will join the event of American Society of Nephrology Kidney Week 2022, hosted from November 3rd. to 6th.
RemeGen Releases Phase II Clinical Study Data for Treatment of Myasthenia Gravis in Chinese Patients
RemeGen Co., Ltd., a commercial-stage biotechnology company, recently released data from the Phase II clinical study of its proprietary novel fusion protein Telitacicept for the treatment of myasthenia gravis in Chinese patients, showing positive results.
RemeGen Receives Orphan Drug Designation from FDA for Telitacicept for the Treatment of Myasthenia Gravis
RemeGen Co., Ltd. ("RemeGen" or "the Company") (9995.HK, SHA: 688331), a commercial-stage biotechnology company, announced that the U.S. Food and Drug Administration (FDA) has granted orphan-drug designation (ODD) for its proprietary novel fusion protein Telitacicept (RC18) for the treatment of myasthenia gravis (MG).
RemeGen to Present Three Studies on Disitamab Vedotin at 2022 ASCO Annual Meeting
RemeGen Co., Ltd., a commercial-stage biotechnology company, announced that three abstracts for disitamab vedotin have been selected for poster discussions by the 2022 American Society of Clinical Oncology Annual Meeting that will be held from June 3 to June 7 2022 in Chicago, USA.
RemeGen Reiterates Commitment to Its Battle Against Autoimmune Disease on World Strengthened Immunity Day 2021
YANTAI, China , Dec. 14, 2021 /PRNewswire/ -- To celebrate World Strengthened Immunity Day, RemeGen Co., Ltd. (9995.HK), a commercial-ready biotechnology company, reiterated its commitment to discovering, developing, and producing best-in-class biological drugs for autoimmune diseases, to create clinical value, and meet the major unmet clinical needs of the world. Since 19
RemeGen's Telitacicept and Disitamab Vedotin Enter China's National Reimbursement Drug List for SLE and Gastric Cancer Treatment
RemeGen Co., Ltd. announced that two of its innovative drugs, a dual-targeted TACI-Fc fusion protein, Telitacicept for treating systemic lupus erythematosus and a novel antibody-drug conjugate, Disitamab Vedotin for treating locally advanced or metastatic gastric cancer, have been officially included in this year's National Reimbursement Drug List.
Seagen and RemeGen Announce Exclusive Worldwide License and Co-Development Agreement for Disitamab Vedotin
Seagen Inc., a world leader and pioneer in antibody-drug conjugate therapies, and RemeGen Co., Ltd., a leading innovative biopharmaceutical company in China, announced that the two companies have entered into an exclusive worldwide licensing agreement to develop and commercialize disitamab vedotin, a novel HER2-targeted ADC.